Healthcare - Biotechnology - NASDAQ - US
$ 1.1
0 %
$ 307 M
Market Cap
-1.39
P/E
CASH FLOW STATEMENT
-164 M
OPERATING CASH FLOW
184 M
INVESTING CASH FLOW
1.74 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Lyell Immunopharma, Inc.
| Net Income | -235 M |
| Depreciation & Amortization | 20.2 M |
| Capital Expenditures | -2.69 M |
| Stock-Based Compensation | 47.1 M |
| Change in Working Capital | 3.42 M |
| Others | 2.14 M |
| Free Cash Flow | -166 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (234.6) | (183.1) | (250.2) | (204.5) | (129.4) |
| Depreciation & Amortization | 20.2 | 18.0 | 13.6 | 4.3 | 1.3 |
| Deferred Income Tax | 0 | 2.3 | 39.5 | (5.6) | (1.5) |
| Stock Based Compensation | 47.1 | 81.9 | 62.2 | 33.3 | 15.7 |
| Other Operating Activities | 0.2 | (6.7) | 4.6 | 12.0 | 42.6 |
| Change in Working Capital | 3.4 | (82.0) | 4.0 | (0.3) | 110.8 |
| Cash From Operations | (163.7) | (169.6) | (126.2) | (160.9) | 39.5 |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (2.7) | (24.3) | (65.5) | (51.5) | (16.0) |
| Other Items | 186.7 | 12.7 | (56.1) | (222.0) | (406.4) |
| Cash From Investing Activities | 184.0 | (11.5) | (121.6) | (273.5) | (422.4) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | (0.5) | (0.5) | 0 | (16.1) | (0.2) |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.7 | 10.6 | 9.4 | 488.6 | 351.3 |
| Cash From Financing Activities | 1.7 | 10.6 | 401.2 | 476.8 | 351.2 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 22.1 | (170.5) | 153.4 | 42.4 | (31.8) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (166.4) | (193.8) | (191.8) | (212.4) | 23.4 |